TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37704499
Drug: Second booster
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second booster doses of monovalent COVID-19 vaccines (AZD1222, Ad26.COV2.S, CoronaVac, BNT162b2)
Study: 37704499
Drug: First booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: First booster doses of monovalent COVID-19 vaccines
Study: 37704753
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (palbociclib) in combination with aromatase inhibitors (AI) or fulvestrant (FUL)
Study: 37704942
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (two oral capsules daily for three months)
Study: 37704984
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) for chronic pain (10 weeks)
Study: 37705074
Drug: Mobile-based coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile-based coaching intervention (WeChat mini-program) with 180 educational videos for 6 months and standard treatment
Study: 37705369
Drug: Hybrid approach
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid approach using drug-eluting stent (DES) and drug-coated balloon (DCB)
Study: 37705424
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alglucosidase alfa 20 mg/kg body weight, single intravenous dose
Study: 37705972
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (including rituximab and abatacept)
Study: 37706025
Drug: Wharton Jelly-derived
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) - 1 intravenous infusion of 1 × 10
Study: 37706457
Drug: Auricular Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular Point Acupressure (APA) treatment administered by nurses for 3 days, with patients instructed to stimulate the points 3 times per day for 3 minutes each time.
Study: 37706580
Drug: ATG-targeted dosing
Normalized name: ATG-101
DrugBank: ATG-101 (DB17162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-targeted dosing strategy
Study: 37706580
Drug: Conventional fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fixed ATG dose (historical control)
Study: 37707791
Drug: Durvalumab (anti-PD-L1)
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (anti-PD-L1) monotherapy
Study: 37707820
Drug: Individualized stereotactic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized stereotactic ablative radiotherapy (SABR) with doses ranging from 25 Gy in 1 fraction for peripheral tumors (0-10 cm3) to 60 Gy in 8 fractions for central tumors (>30 cm3).
Study: 37707942
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm received daily walk step reminders to walk at least 5000 steps per day
Study: 37707944
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Therapy (iCBT) with Virtual Reality Exposure Therapy (VRET) - 14-week program including 9 web-based modules and 5 individual counseling sessions (2 VRET sessions)
Study: 37707956
Drug: Inhibitors and
Normalized name: ACE inhibitors and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors and mimics of miRNAs
Study: 37708435
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health application designed to increase AUD treatment engagement
Study: 37708528
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (17-g dose by mouth on postoperative day 1)
Study: 37708528
Drug: Docusate sodium
Normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docusate sodium (100 mg starting the day of surgery and continued twice daily at home)
Study: 37708629
Drug: Apalutamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide plus androgen-deprivation therapy (ADT)
Study: 37708912
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus HIPEC (100 mg/m²)
Study: 37709280
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg + placebo (DX1)
Study: 37709280
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg + dexamethasone 24 mg (DX2)
Study: 37709305
Drug: ACT for
Normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT for informal caregiver (ACT-IC) intervention delivered over a 9-week period consisting of a collaborative goal-setting session, nine online ACT modules, nine telephone-based motivational coaching sessions and 6 monthly booster sessions following the main intervention period.
Study: 37709311
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of oral vancomycin every 6 hours for 10 days
Study: 37709314
Drug: nCRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCRT + immunotherapy
Study: 37709320
Drug: Intravenous sivelestat
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous sivelestat sodium for up to 7 days
Study: 37709337
Drug: Powdered meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered meal replacement (PMR) group: replacing morning and afternoon snacks daily with a PMR for 12 weeks
Study: 37709661
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550 (9 mg or 18 mg)
Study: 37710005
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) as second-line therapy
Study: 37710178
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of lipid lowering therapy
Study: 37710198
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen (5 mg/day) for 5 years
Study: 37710376
Drug: Suboptimal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal protein intake (0.2 g·kg-1·d-1)
Study: 37710376
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein intake (1.2 g·kg-1·d-1)
Study: 37710376
Drug: Excess protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excess protein intake (2.0 g·kg-1·d-1)
Study: 37710376
Drug: Recommended protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended protein intake for males (1.81 g·kg-1·d-1)
Study: 37710376
Drug: Recommended protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended protein intake for females (1.89 g·kg-1·d-1)
Study: 37710376
Drug: Upper 95%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper 95% confidence interval protein intake (~1.85 g·kg-1·d-1)
Study: 37711193
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation
Study: 37711198
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (5ug), QID dosing
Study: 37711623
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with ITI-3000 (a cancer vaccine targeting MCPyV-LT)
Study: 37712585
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B birth dose along with routine immunisation vaccines
Study: 37712728
Drug: Maximal expiratory
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal expiratory pressure during induced cough (measured with slow instillation of 2mL of a 0.9% saline solution)
Study: 37712908
Drug: Eculizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab treatment for >35 days
Study: 37712984
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (ART)
Study: 37713020
Drug: Relugolix (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (120 mg orally once daily after single 360 mg loading dose)
Study: 37713020
Drug: Relugolix with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix with concomitant CV agents
Study: 37713527
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous cefoxitin
Study: 37713598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of WJ-MSC and Magnovision
Study: 37713684
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and clopidogrel on top of aspirin (ADAPT)
Study: 37715029
Drug: Anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 therapy with thyroid dysfunction
Study: 37715173
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid
Study: 37715249
Drug: BCN-led group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCN-led group cognitive behavioural therapy (CBT)
Study: 37715270
Drug: Quizartinib combined
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib combined with high-dose Ara-C plus mitoxantrone (HAM)
Study: 37715270
Drug: Intensive salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive salvage therapy
Study: 37715730
Drug: Indoximod-based combination
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoximod-based combination therapy with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles)
Study: 37715730
Drug: Indoximod-based combination
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoximod-based combination therapy with palliative conformal radiation
Study: 37715730
Drug: Indoximod-based combination
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoximod-based combination therapy
Study: 37715767
Drug: Youth Development
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth Development Accounts (YDA) treatment, n=471 girls
Study: 37715860
Drug: Pegcetacoplan treated
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan treated monthly (PM)
Study: 37716204
Drug: ACT-IN plus
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-IN plus treatment as usual (TAU)
Study: 37716204
Drug: TAM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM plus treatment as usual (TAU)
Study: 37716365
Drug: Bivalent SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine (5 μg of ancestral [D614] and 5 μg of beta [B.1.351] variant spike protein, with AS03 adjuvant), administered as two 0.5 mL intramuscular injections, 21 days apart.
Study: 37716365
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline), administered as two 0.5 mL intramuscular injections, 21 days apart.
Study: 37716448
Drug: DAPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT plus rivaroxaban 2.5mg twice daily for 4 weeks
Study: 37716893
Drug: Brief Cognitive-Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive-Behavioural Therapy (CBT) intervention, six sessions
Study: 37716990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rapid diagnostic testing and pharmacist-led de-escalation
Study: 37716990
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with anti-viral medications
Study: 37716990
Drug: Total duration
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total duration of any antibiotic
Study: 37717638
Drug: SHHC-2.0 intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHHC-2.0 intervention (24 weeks of twice-weekly experiential nutrition education and group-based physical activity classes)
Study: 37717786
Drug: Hypofractionated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated proton beam radiation therapy (PBT) at dose level 1 (DL1) - 5 Gy × 5 fractions, administered on days 15 to 19 in a 28-day cycle before starting cycle 7 of mFFX.
Study: 37717786
Drug: Hypofractionated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated proton beam radiation therapy (PBT) at dose level 2 (DL2) - 5 Gy × 5 fractions, administered on days 8 to 12 in a 21-day cycle before starting cycle 7 of mFFX.
Study: 37718234
Drug: Technetium-99m-mercaptoacetyltriglycine diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium-99m-mercaptoacetyltriglycine diuretic renography at timepoint 1
Study: 37718721
Drug: Pegozafermin 27
Normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegozafermin 27 mg once weekly for 20 weeks
Study: 37718930
Drug: Mini-dose Bier's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-dose Bier's block
Study: 37719091
Drug: Increased physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased physical activity (500 steps/day weekly until 10,000 steps/day)
Study: 37719417
Drug: BCG-Denmark vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-Denmark vaccination (1 intradermal dose of 0.1 mL)
Study: 37720013
Drug: BRIGHT (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRIGHT (5 weekly psychologist-led video tele-CBT sessions)
Study: 37720013
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control (dose-and delivery matched survivorship education)
Study: 37720456
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - eight sessions of group-based CBT (every 2-3 weeks)
Study: 37720540
Drug: Sensor Augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor Augmented Pump (SAP) therapy
Study: 37720540
Drug: Multiple Daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Daily Injection (MDI) therapy
Study: 37720564
Drug: Omadacycline treatment
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline treatment at 16× the MIC for 72 hours
Study: 37720591
Drug: Mobile app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app-based self-guided psychological intervention (Nałogometr) delivered via smartphone app for four weeks, including mindfulness and cognitive behavioral therapy modules.
Study: 37720695
Drug: Early 75 g
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early 75 g OGTT at 12-15 weeks of gestation
Study: 37720695
Drug: Lowering postload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering postload glucose values (75 g OGTT cut-off values of 5.1, 8.9, and 7.8 mmol/L)
Study: 37721470
Drug: Adjunctive COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive COX-2 inhibitor etoricoxib
Study: 37721581
Drug: novel somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel somatostatin receptor (SSTR) antagonist
Study: 37721754
Drug: Cetuximab maintenance
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab maintenance therapy after FOLFIRI plus cetuximab induction therapy
Study: 37721754
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after FOLFIRI plus cetuximab induction therapy
Study: 37721786
Drug: 12-week tele-RHB
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week tele-RHB program along with CPAP therapy
Study: 37721786
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy alone
Study: 37721786
Drug: tele-RHB program
Approvals — FDA: no, EMA: no, PMDA: no
Description: tele-RHB program and CPAP therapy
Study: 37721791
Drug: AT-Patch device
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-Patch device
Study: 37721795
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light (BL) therapy
Study: 37721795
Drug: Dim Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim Light (DL) therapy
Study: 37721964
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug treatments (IDA, MoxDA)
Study: 37721990
Drug: Oral Δ
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Δ
Study: 37722354
Drug: ibrutinib +
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ibrutinib + CIT (560 mg daily plus 6 cycles of BR/R-CHOP)
Study: 37722354
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + CIT (placebo daily plus 6 cycles of BR/R-CHOP)
Study: 37722662
Drug: Integrated malaria-helminth
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated malaria-helminth treatment approach
Study: 37723108
Drug: Remotely administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely administered adherence programme
Study: 37723272
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment (ST)
Study: 37723467
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic medication
Study: 37725026
Drug: Standard whole-gland
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole-gland radiation therapy of 77 Gy
Study: 37725234
Drug: 2.9 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 mm diameter bone-level-tapered implant
Study: 37725613
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose physical therapy intervention initiated in the NICU and continuing to 12 months of age, with twice-weekly sessions and caregiver-guided activities
Study: 37725680
Drug: Nesiritide treatment
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide treatment in decompensated heart failure
Study: 37725919
Drug: Patiromer (8.4-33.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (8.4-33.6 g/day for 12 months)
Study: 37726068
Drug: Miracle fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miracle fruit (MF) tablet
Study: 37726695
Drug: Atezolizumab (PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (PD-L1 directed immunotherapy, IV infusion, 1680 mg, every 28 days for one year if tolerated)
Study: 37726695
Drug: Atezolizumab (PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (PD-L1 directed immunotherapy)
Study: 37726771
Drug: Education Outside
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education Outside the Classroom (EOtC) intervention: a two-day training course for teachers followed by implementation of EOtC >5 hours weekly over one school year.
Study: 37726786
Drug: Patient-derived tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-derived tumor organoids (PDTO) cultured in a medium supplemented with growth factors and signal pathway inhibitors.
Study: 37726786
Drug: PDTO response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PDTO response to chemo-ICB (immune checkpoint blocker and chemotherapy).
Study: 37726820
Drug: Plant-based omega
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based omega fatty acid supplement
Study: 37726820
Drug: Both supplements
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both supplements combined
Study: 37726823
Drug: BNI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNI plus facilitated initiation of medications for alcohol use disorder (BNI + MAUD)
Study: 37726823
Drug: BNI +
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BNI + MAUD + initiation of computer-based training for cognitive behavioral therapy (CBT4CBT)
Study: 37727387
Drug: Intraoperative slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex)
Study: 37727387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dexamethasone implant)
Study: 37728115
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs)
Study: 37728142
Drug: Digital self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital self-help plus treatment as usual (TAU)
Study: 37728224
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate 50 μg once daily (QD)